RegeneMed
San Diego · Founded 2003
About RegeneMed
RegeneMed accelerates the development of safer, more effective drugs by providing integrated high throughput platforms incorporating engineered human tissue-based assays. Their patented, proprietary, core technologies enable in vitro growth of engineered human tissues, including liver, GI tract, bone marrow, blood-brain barrier, cardiovascular and neuronal. The first and critical application of these tissue-based in vitro model systems is to replace cell-based assays and animal testing to debottleneck ADME/Tox evaluation, the leading cause of drug failures facing the pharmaceutical industry.
Company Facts
- Founded: 2003
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $1.0M
- Last round: Series Unknown (Jan 2007)
- Website: http://www.regenemed.com
- Phone: +1 8582009531
Industries & Categories
Biotechnology, Health Care
Social Profiles
Canonical: https://fsome.com/organization/regenemed-2441998 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.